Itraconazol Tarbis

Itraconazole, the active ingredient in Itraconazol Tarbis, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of serious fungal infections—including blastomycosis, histoplasmosis, aspergillosis, candidiasis and dermatophyte infections—in adults and children when prescribed by a healthcare professional.

GNH USA supplies Itraconazol Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this essential antifungal agent with full documentation and support for import compliance.

Itraconazole is an azole antifungal used to treat systemic mycoses by inhibiting fungal cell membrane synthesis.

- Blastomycosis: achieves clinical cure and prevents disease progression. - Histoplasmosis: clears infection and reduces relapse risk. - Aspergillosis: controls invasive disease and improves survival. - Candidiasis: resolves systemic and mucosal infections. - Dermatophyte infections: eradicates skin and nail fungal involvement.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Rash: skin erythema or pruritus. - Elevated liver enzymes: mild transaminase rise. - Abdominal pain: discomfort in the upper abdomen. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Stevens‑Johnson syndrome: life‑threatening skin reaction. - Congestive heart failure: worsening of cardiac function. - Visual disturbances: blurred vision or photophobia. - Severe hypokalemia: dangerous low potassium levels. - Interstitial lung disease: pulmonary inflammation.

Before initiating therapy, consider the following safety measures.

- Liver function monitoring: assess baseline and periodic hepatic enzymes. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Cardiac assessment: avoid in patients with congestive heart failure. - Pregnancy and lactation: use only if benefits outweigh risks. - Renal impairment: adjust if severe renal dysfunction. - Store below 25°C: keep in the original container, protect from moisture.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxicity. - QT‑prolonging agents (e.g., quinidine): increase risk of arrhythmia. - Rifampin: markedly reduces itraconazole plasma levels.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): may increase statin exposure and risk of myopathy. - Oral contraceptives: itraconazole can reduce contraceptive efficacy. - Antacids or proton‑pump inhibitors: may decrease itraconazole absorption.